multiple sclerosis

Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Fierce Pharma
Wed, 03/1/23 - 07:08 pm
Roche
Genentech
patents
MS
multiple sclerosis
legal
Tysabri
Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties
Fierce Pharma
Mon, 02/20/23 - 12:42 pm
Novartis
Mitsubishi Chemical
multiple sclerosis
MS
Supreme Court
legal
patents
Gilenya
Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Endpoints
Tue, 01/24/23 - 06:18 pm
Novartis
Supreme Court
Gilenya
patents
generics
multiple sclerosis
MS
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
BioPharma Dive
Wed, 01/4/23 - 10:11 am
FDA
drug approvals
HIV
lymphoma
multiple sclerosis
Gilead Sciences
Roche
TG Therapeutics
MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference
BioSpace
Wed, 10/26/22 - 06:51 pm
Merck
Biogen
Bristol Myers Squibb
MS
multiple sclerosis
ECTRIMS
ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab
Endpoints
Tue, 10/18/22 - 10:36 am
ICER
MS
multiple sclerosis
drug pricing
ublituximab
TG Therapeutics
Novartis' blockbuster Gilenya exposed to generics in short term amid Supreme Court appeal
Fierce Pharma
Fri, 10/14/22 - 10:40 am
Novartis
Gilenya
generics
Supreme Court
MS
multiple sclerosis
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Tue, 09/20/22 - 08:36 pm
Biogen
Novartis
Sandoz
biosimilars
Tysabri
MS
multiple sclerosis
BrainStorm Brings MS Data on Heels of ALS BLA Announcement
BioSpace
Fri, 09/16/22 - 10:19 am
BrainStorm Cell Therapeutics
NurOwn
multiple sclerosis
MS
ACP and partners to launch Covid-19 vaccine study for multiple sclerosis
Clinical Trials Arena
Fri, 09/2/22 - 12:16 pm
Accelerated Cure Project
MS
multiple sclerosis
Quest Diagnostics
vaccines
clinical trials
COVID-19
Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?
Endpoints
Mon, 08/15/22 - 10:23 am
Clene Nanomedicine
multiple sclerosis
MS
clinical trials
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Fierce Pharma
Wed, 07/27/22 - 10:58 am
Novartis
Biogen
multiple sclerosis
MS
Tysabri
biosimilars
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
BioPharma Dive
Mon, 07/25/22 - 09:54 pm
Novartis
FDA
Biogen
biosimilars
Tysabri
MS
multiple sclerosis
Biogen pays $900M to resolve whistleblower's MS kickback suit as competition drags on sales
Fierce Pharma
Wed, 07/20/22 - 11:17 pm
Biogen
whistleblowers
multiple sclerosis
MS
kickbacks
FDA Partially Halts Sanofi’s BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis
Pharma Live
Thu, 06/30/22 - 10:59 am
Sanofi
multiple sclerosis
myasthenia gravis
FDA
tolebrutinib
clinical trials
clinical hold
Novartis' recent Gilenya patent win slips away after appeals court reverses its own prior verdict
Fierce Pharma
Tue, 06/21/22 - 11:45 pm
Novartis
patents
Gilenya
multiple sclerosis
After ulcerative colitis flop, Immunic regains some momentum with multiple sclerosis update
Fierce Biotech
Wed, 06/15/22 - 10:58 am
Immunic
MS
multiple sclerosis
ulcerative colitis
vidofludimus calcium
Research Shows Stem Cells Might Become a Game Changer for Multiple Sclerosis
BioSpace
Thu, 06/9/22 - 10:48 am
R&D
stem cells
multiple sclerosis
MS
Biogen taps digital therapeutics biotech for music-based therapy to help people with MS improve their walking
Endpoints
Sun, 05/8/22 - 12:10 pm
Biogen
digital healthcare
digital therapeutics
MedRhythms
MS
multiple sclerosis
Sanofi moves patients out of Ukraine warzone in 'Herculean effort' to preserve MS trials
Fierce Biotech
Fri, 04/29/22 - 10:40 am
Sanofi
clinical trials
Ukraine
Russia
multiple sclerosis

Pages